GPC Biotech AG is a publicly traded biopharmaceutical company focused on anticancer drugs.
GPC Biotech's lead product candidate is satraplatin, an oral platinum compound.
The Company has various anti-cancer programs in research and development that leverage its expertise in kinase inhibitors.
GPC Biotech AG is headquartered in Martinsried/Munich (Germany) and has a wholly owned U.S. subsidiary in Princeton, New Jersey.
GPC Biotech offers its employees a variety of benefits and incentives, including a remuneration system rewarding outstanding performance and long-term stock option plans. The Company also invests in the further education and professional development of its employees.
